Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients-Reference-Cited by-同舟云学术

Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients

Published:2003-05 Issue:7 Volume:17 Page:1023-1028
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:AIDS

Author:

Pérez-Olmeda Mayte,Núñez Marina,Romero Miriam,González Juan,Castro Angeles,Arribas José Ramón,Pedreira José,Barreiro Pablo,García-Samaniego Javier,Martín-Carbonero Luz,Jiménez-Nácher Inmaculada,Soriano Vincent

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference22 articles.

1. Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C

2. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus

3. Hepatitis C Virus Infection

4. Peginterferon Alfa-2a in Patients with Chronic Hepatitis C

5. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Cited by 182 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revolutionizing HCV Therapy: microRNA Approaches in New Era of Treatment;Liver Cancer - Multidisciplinary Approach;2024-07-11

2. HCV treatment in Sardinian HIV-HCV coinfected patients: a real-life perspective study on safety, efficacy, and immune reconstitution;Expert Review of Anti-infective Therapy;2022-10-07

3. Low Incidence of Hepatocellular Carcinoma after Antiviral Therapy in Patients with Chronic Hepatitis C and Hemophilia;Journal of Clinical Medicine;2022-03-07

4. Drug-based therapeutic strategies for COVID-19-infected patients and their challenges;Future Microbiology;2021-12

5. High rate of sustained virological response with direct‐acting antivirals in haemophiliacs with HCV infection: A multicenter study;Liver International;2020-01-06